Calidi Biotherapeutics Advances CLD-401 Toward Clinic with Key Partnerships and $6.5M Raise
Event summary
- Partnered with Avance Clinical to accelerate CLD-401 clinical trial initiation in Australia
- Expects to file IND for CLD-401 by end of 2026 after positive FDA Type D meeting feedback
- Collaborated with Matica Bio for GMP manufacturing of CLD-401
- Presented new in situ T-cell engagers data at 2026 AACR-IO conference
- Raised $6.5 million in public offering and ATM sales in Q1 2026
The big picture
Calidi's strategic moves position CLD-401 for accelerated clinical development, leveraging international partnerships and positive regulatory interactions. The $6.5 million raise strengthens its balance sheet as it advances its RedTail platform in the competitive oncolytic virus space. Success hinges on maintaining this momentum through critical 2026 milestones.
What we're watching
- Regulatory Pathway
- Whether FDA feedback will support timely IND filing and clinical initiation by year-end 2026
- Clinical Execution
- The pace at which Australian trial initiation will progress under the Avance Clinical partnership
- Financial Sustainability
- How the $6.5 million raise will extend cash runway and support operational milestones
Related topics